1. Home
  2. BTGO vs ANL Comparison

BTGO vs ANL Comparison

Compare BTGO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BitGo Holdings Inc. Class A Common Stock

BTGO

BitGo Holdings Inc. Class A Common Stock

N/A

Current Price

$5.27

Market Cap

692.3M

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$13.02

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTGO
ANL
Founded
2013
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
692.3M
611.1M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
BTGO
ANL
Price
$5.27
$13.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
1
Target Price
$14.83
$20.00
AVG Volume (30 Days)
994.7K
200.8K
Earning Date
05-13-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
$34.41
N/A
P/E Ratio
$10.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.67
$0.88
52 Week High
$15.30
$17.25

Technical Indicators

Market Signals
Indicator
BTGO
ANL
Relative Strength Index (RSI) 52.19 54.83
Support Level $4.71 $12.41
Resistance Level $5.72 $13.29
Average True Range (ATR) 0.31 1.04
MACD 0.06 -0.04
Stochastic Oscillator 72.24 43.57

Price Performance

Historical Comparison
BTGO
ANL

About BTGO BitGo Holdings Inc. Class A Common Stock

BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: